Edoxaban vs warfarin in patients with nonvalvular atrial fibrillation in the US Food and Drug Administration approval population: An analysis from the Effective Anticoagulation with Factor Xa Next Generation in Atrial Fibrillation-Thrombolysis in Myocardial Infarction 48 (ENGAGE AF-TIMI 48) trial. [electronic resource]
Producer: 20160614Description: 144-51 p. digitalISSN:- 1097-6744
- Aged
- Anticoagulants -- administration & dosage
- Atrial Fibrillation -- complications
- Blood Coagulation -- drug effects
- Dose-Response Relationship, Drug
- Double-Blind Method
- Drug Approval
- Factor Xa -- drug effects
- Factor Xa Inhibitors -- administration & dosage
- Female
- Humans
- Male
- Myocardial Infarction -- complications
- Pyridines -- administration & dosage
- Stroke -- blood
- Thiazoles -- administration & dosage
- Thrombolytic Therapy -- methods
- United States
- United States Food and Drug Administration
- Warfarin -- administration & dosage
No physical items for this record
Publication Type: Journal Article; Multicenter Study; Randomized Controlled Trial
There are no comments on this title.
Log in to your account to post a comment.